In the press

Matthew Read comments on the Herald tender in Investment Week

Biotech trusts top performance charts in February

Matthew Read comments on the tender result in Robin Amos’ article:

“This has been one of the investment company sector’s great long-term success stories and, under Katie Potts, it offers a genuinely differentiated exposure to smaller quoted technology companies that is hard to replicate elsewhere. With around £650m of net assets remaining, the trust still has meaningful scale and, hopefully, can now move on and rebuild from here.”

Read the article here